Incannex Healthcare Inc. has announced positive topline results from its RePOSA Phase 2 clinical trial evaluating IHL-42X, a novel oral drug candidate for the treatment of obstructive sleep apnea (OSA). The trial demonstrated statistically and clinically significant improvements across key clinical endpoints, with IHL-42X reducing the apnea-hypopnea index by up to 83% from baseline. The study, which was a randomized, double-blind, placebo-controlled clinical trial, included 121 adult participants with moderate to severe OSA. The findings underscore IHL-42X's potential as a transformative therapy, given its robust efficacy and outstanding safety profile. With no approved oral pharmaceutical treatments currently available for OSA, Incannex is preparing for an End-of-Phase 2 meeting with the FDA to discuss the most efficient path to registration and to optimize the Phase 3 trial design and regulatory strategy. The company continues to evaluate all clinical data and aims to complete the full Clinical Study Report in the coming months.